Brain Tumor News!

Note: The comments under each article title are the opinion of our president, Al Musella, DPM,
and do not reflect official policy of the Musella Foundation!

06/14/03 Phase II study of neoadjuvant BCNU and temozolomide for newly diagnosed anaplastic glioma        

06/14/03 Preradiation combination of temozolomide (TMZ) and BCNU as primary treatment before radiotherapy (RT) in inoperable newly diagnosed glioblastoma multiforme (GBM)        

06/14/03 Combination temozolomide (T) and pegylated liposomal doxorubicin (C) in patients with recurrent glioblastoma multiforme (GBM)        

06/14/03 Intracavitary placement of lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma        

06/14/03 Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme        

06/14/03 STI 571/hydroxyurea in progressive, pretreated glioblastoma (GB) patients (pts.)        

06/14/03 Safety and efficacy of temozolomide concomitant and sequential to radiotherapy in glioblastoma multiforme: Results of a phase II multicentric study        

06/14/03 Comparison of survival of patients in the phase I study of motexafin gadolinium (MGd) with radiation therapy (RT) for glioblastoma multiforme (GBM), with a matched cohort of patients from the RTOG RPA glioma database        

06/14/03 C11-methionine PET in radiotherapy planning of glioma        

06/14/03 Phase II multicenter study of 7/7 dosing of temozolomide (TMZ) in patients (pts) with newly diagnosed pure and mixed anaplastic oligodendroglioma (AO/MAO)        

06/14/03 Survival analysis for patients with primary brain tumors treated with temozolomide        

06/14/03 Temozolomide chemotherapy for progressive low grade glioma        

06/14/03 Phase II trial of ZD1839 for patients with first relapse glioblastoma        

06/14/03 Phase I trial of temozolomide plus O6-benzylguanine in the treatment of patients with recurrent or progressive cerebral anaplastic gliomas        

06/14/03 A phase I trial of extended daily dosing of temozolomide and BCNU for malignant gliomas after radiation therapy        

06/14/03 Loco-regional radioimmunotherapy of malignant glioma by means of a humanised antibody hR3 (raised against epidermal growth factor receptors) labelled with Y-90        

06/14/03 Clinical outcome and distribution measure of a recombinant chimeric protein composed of transforming growth factor alpha and a mutated Pseudomonas exotoxin (TP-38) via convection-enhanced microinfusion on a phase I study for malignant brain tumor        

06/14/03 Up-front chemotherapy temozolomide in the treatment of Gliomatosis Cerebri: Analysis of 33 patients        

06/14/03 A phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme        

---

Displaying Stories 5661 to 5680 of 7668
Previous 20           Next 20